Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention
about
Effects of exercise training on circulating levels of Dickkpof-1 and secreted frizzled-related protein-1 in breast cancer survivors: A pilot single-blind randomized controlled trialTreatment of multiple myeloma bone disease: experimental and clinical data.High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes.Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblastThe genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model.Management of bone disease in multiple myeloma.Genetic Approaches To Identifying Novel Osteoporosis Drug Targets.DKK1 promotes migration and invasion of non-small cell lung cancer via β-catenin signaling pathway.Current treatment options of T cell-associated immunotherapy in multiple myeloma.In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy.Predictive value of 18 F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma.Human DKK1 and human HSP70 fusion DNA vaccine induces an effective anti-tumor efficacy in murine multiple myeloma.Homozygous Dkk1 Knockout Mice Exhibit High Bone Mass Phenotype Due to Increased Bone Formation.MMSA-1 expression pattern in multiple myeloma and its clinical significance.
P2860
Q29248172-CEA44C11-2674-41D0-AF93-954B06FB52DDQ30868833-24F61332-00C0-4D41-A72F-EC1988435B56Q35755147-EDECBF33-C56B-430F-A407-F39ACDA4CD80Q36086488-7C8EFD13-09AE-4BF5-807F-F890EFA79F10Q36962747-C2FCEE28-C666-4E07-B0E0-6939C4D07E1CQ37723278-F8FF0DFC-422D-4687-8019-1DE56CC64022Q38179039-2AFCA602-CF40-459E-AAC4-9D49F1656DAAQ38400680-528A4FA2-CEE3-4777-80CF-70594D5B93DEQ38698123-5186BE76-6FB6-43CB-B00D-0FEB637D16B4Q39102170-CC48D9CC-267F-40E0-90E7-264D3A25CFC6Q47723896-A0737328-E34E-457C-A637-44EB0465C70BQ47829053-2A6D7BAD-8F66-4922-BC7B-1C2755F6EBAAQ48144595-EB5F5ED3-8B59-4A8A-9687-9A72B655CD7AQ48507398-5252D7BE-BE58-4007-96A1-3E0E7475C3F9Q50145648-9D7E4DB1-A2FA-435F-8160-536ED492A947Q52907776-9C1392A3-9C19-4592-84D3-C6B0BB374E50
P2860
Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Dickkopf-1 is a key regulator ...... s for therapeutic intervention
@ast
Dickkopf-1 is a key regulator ...... s for therapeutic intervention
@en
Dickkopf-1 is a key regulator ...... s for therapeutic intervention
@nl
type
label
Dickkopf-1 is a key regulator ...... s for therapeutic intervention
@ast
Dickkopf-1 is a key regulator ...... s for therapeutic intervention
@en
Dickkopf-1 is a key regulator ...... s for therapeutic intervention
@nl
prefLabel
Dickkopf-1 is a key regulator ...... s for therapeutic intervention
@ast
Dickkopf-1 is a key regulator ...... s for therapeutic intervention
@en
Dickkopf-1 is a key regulator ...... s for therapeutic intervention
@nl
P2093
P2860
P1433
P1476
Dickkopf-1 is a key regulator ...... s for therapeutic intervention
@en
P2093
François X Claret
Fuling Zhou
Huanjin Song
P2860
P304
P356
10.1016/J.BLRE.2013.08.002
P577
2013-09-02T00:00:00Z